Fundraising Fox

Candid Therapeutics

San Diego, US · Founded 2024 · Delaware corporation · 7 known investors

candidrx.com ↗

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells. The company focuses on creating therapies that are more effective and easier to administer than existing antibody and cell therapy approaches.

BiotechHealthtechin /candidrx

Founders & leadership

KS
Ken SongChairman, President and CEO
KS
Kenneth Song, M.D.Executive Officer, Director
AK
Arvind KushExecutive Officer
TL
Timothy Lu, M.D.Executive Officer
BH
Bernie Huyghe, Ph.D.Executive Officer
JT
Jeffrey Tong, Ph.D.Director
AR
Aaron Royston, M.D.Director
MR
Michael Rome, M.D.Director

Investors · 7

Foresite CapitalLarkspur
OrbiMedNew York · $1M – $75M
Samsara BioCapitalPalo Alto
TCG CrossoverPalo Alto
Third Rock VenturesBoston · $100K – $5M
venBio PartnersSan Francisco
Vida VenturesLos Angeles

Reported raises · per SEC filings

Form D private placements
▶$206.2MraisedSep 2024 · 33 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey Tong, Ph.D.Director
  • Arvind KushExecutive Officer
  • Timothy Lu, M.D.Executive Officer
  • Kenneth Song, M.D.Executive Officer, Director
  • Aaron Royston, M.D.Director
  • Bernie Huyghe, Ph.D.Executive Officer
  • Michael Rome, M.D.Director
Offering amount
$206.2M
Amount sold
$206.2M
First sale
Aug 2024
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news